Urinary excretion of glomerular basement membrane-related peptides in children with renal disorders

Abstract

Urinary excretion of glomerular basement membrane (GBM)-related peptides was analysed in 72 patients with a variety of renal diseases by immunoblotting using polyclonal antibodies against either collagenase or pepsin digests of human GBM. The specificity of the antibodies was verified by elution of antibodies bound to urinary GBM-related peptides on nitrocellulose blots and demonstration of reactivity of the eluted antibodies with the respective GBM digests. Furthermore, six mice immunized with urinary GBM-related peptides all developed focal linear deposits of mouse IgG along their GBM, linear and mesangial deposits of C3 in the glomeruli and serum antibodies reactive with human GBM. Monoclonal antibodies against urinary GBM-related peptides of one of the mice reacted with different peptides of the non-collagenous and collagenous domains of type IV collagen, the major structural protein of GBM. In the majority of the 75 patients' urines tested, excretion of GBM-related peptides with molecular weights of 33, 50, 80 and 150 kilodaltons (kD) was detectable. Patients with a diminished glomerular filtration rate (GFR) demonstrated excretion of the 33 kD peptide more frequently (91%) and never of the 80 kD peptide as compared with patients with normal GFR (33 kD [42%] 80 kD [87%]). The pattern of urinary GBM-related peptides was not specific for the underlying renal disease as in Alport's syndrome.

Transarterial chemoembolization versus surgical resection for giant hepatocellular carcinoma under the different status of capsule: a retrospective study

“…Jin et al found that surgery seems to be more effective than TACE for a solitary large HCC of BCLC stage A (P<0.01) (12). However, because of the more aggressive tumor biology, G-HCC patients accompanied by vascular invasion, satellite nodules always be difficult to take resection and had the high rate of recurrence after surgical resection (13)(14)(15), therefore some scholars choose the TACE for G-HCC, Xue et al found the survival rates of huge HCC patients who received TACE was 33% at 1 year 13% at 3 years and 10% at 5 years, they thought TACE was suitable and safe for huge HCC and is particularly suitable for patients with good liver function and BCLC B stage (16). However, the first-line treatment for G-HCC is also controversial.…”